Lecy Albarado, APRN
Psychiatric/Mental Health · Scott, LANPI 1346295458
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,925 of the $33,641 with a category attached, or 71.1%. AbbVie accounts for 82.7% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $14,036 and has fallen 88.8% since, to $1,576 in 2025. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 513 payments — averaging $65.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$847
- Corium, LLC$830
- Alkermes, Inc.$795
- Otsuka America Pharmaceutical, Inc.$502
- Sunovion Pharmaceuticals Inc.$463
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$23,92571%
- Travel & lodging$1,8365%
- Food & beverage$7,80923%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 163 | $27,837 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $847 |
| Corium, LLC | 47 | $830 |
| Alkermes, Inc. | 39 | $795 |
| Otsuka America Pharmaceutical, Inc. | 34 | $502 |
| Sunovion Pharmaceuticals Inc. | 50 | $463 |
| Teva Pharmaceuticals USA, Inc. | 10 | $261 |
| Neurocrine Biosciences, Inc. | 11 | $240 |
| Lundbeck LLC | 12 | $235 |
| Tris Pharma Inc | 12 | $217 |
| Johnson & Johnson | 11 | $203 |
| Axsome Therapeutics, Inc. | 7 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $155 |
| Noven Therapeutics, LLC | 7 | $144 |
| Avanir Pharmaceuticals, Inc. | 12 | $137 |
| Vanda Pharmaceuticals Inc. | 6 | $126 |
| Bausch Health US, LLC | 7 | $112 |
| Ironshore Pharmaceuticals Inc. | 6 | $111 |
| Neos Therapeutics, LP | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Adlon Therapeutics L.p. | 2 | $40 |
| Eisai Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Harmony Biosciences LLC | 1 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,641 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 25 | $79,533 |
| Austedo XrDeutetrabenazine | 14 | $71,117 |
| VraylarCariprazine Hcl | 43 | $64,282 |
| NuedextaDextromethorphan Hbr/Quinidine | 28 | $42,851 |
| TrintellixVortioxetine Hydrobromide | 61 | $32,957 |
| RexultiBrexpiprazole | 16 | $24,085 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $8,203 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $5,299 |
| MydayisDextroamphetamine/Amphetamine | 12 | $4,095 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 112 | $3,997 |
| Ziprasidone Hcl | 14 | $3,143 |
| Vilazodone Hcl | 42 | $2,905 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $1,836 |
| Aripiprazole | 54 | $1,776 |
| Bupropion XlBupropion Hcl | 113 | $1,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $203 | $79,53325 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $261 | $71,11714 claims |
| AbbVieVraylar | $27,837 | $64,28243 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $137 | $42,85128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $155 | $41,16083 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $502 | $24,08516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Scott
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Michelle DyerLake Charles$33K
- Shantell BurnsPrairieville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.